富瑞:升永升生活服務(1995.HK)目標價至8.91港元 維持“買入”評級
富瑞發表研究報告指,永升生活服務(1995.HK)昨天公佈盈喜,由於在管面積、增值服務以及青島雅園的強勁增長,公司2019年純利按年增長1倍至2億元人民幣(下同),與該行預測的65%核心盈利增長相符。該行將目標價由7.72港元上調至8.91港元,維持“買入”評級。
該行指,公司早前以總代價860萬元宣佈收購青島銀盛泰50%的股份,銀盛泰目前在山東省管理18個項目,總建築面積為320萬平方米,相當於集團當前投資組合規模的5%。該行認為,新收購項目可為集團帶來潛在的利潤空間上升、龐大的增值服務擴張空間,以及銀盛泰吸引的估值。因此該行將集團2020-21年盈利上調3-4%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.